Glanbia (OTCMKTS:GLAPF)‘s stock had its “buy” rating restated by equities research analysts at Kepler Capital Markets in a report released on Monday, AnalystRatings.com reports.
Several other equities research analysts also recently weighed in on the company. Barclays reaffirmed an “equal weight” rating on shares of Glanbia in a research report on Friday, April 24th. Morgan Stanley reaffirmed an “overweight” rating on shares of Glanbia in a research report on Wednesday, June 17th.
Shares of GLAPF opened at $11.58 on Monday. The business’s 50-day moving average is $11.19 and its two-hundred day moving average is $10.97. Glanbia has a fifty-two week low of $9.30 and a fifty-two week high of $16.27.
Glanbia plc operates as a nutrition company. It operates through three segments: Glanbia Performance Nutrition, Glanbia Nutritionals, and Glanbia Ireland. The Glanbia Performance Nutrition segment manufactures and sells sports nutrition and lifestyle nutrition products in various formats, including powders, ready-to-eat bars and snacking foods, and ready-to-drink beverages through various channels, such as specialty retail, e-Commerce, and gyms, as well the food, drug, mass, and club channels.
Featured Article: Death Cross
Receive News & Ratings for Glanbia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glanbia and related companies with MarketBeat.com's FREE daily email newsletter.